GLOBALT Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

GLOBALT Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28M	Sell	4,583 -190	-4%	-$84.2K	0.08%	112
2026 Q1	$2.13M	Buy	4,773 +30	+0.6%	+$14K	0.08%	113
2025 Q4	$2.15M	Sell	4,743 -29	-0.6%	-$12.5K	0.08%	111
2025 Q3	$1.87M	Sell	4,772 -2,513	-34%	-$1.05M	0.07%	116
2025 Q2	$3.24M	Sell	7,285 -410	-5%	-$189K	0.12%	96
2025 Q1	$3.73M	Sell	7,695 -293	-4%	-$137K	0.15%	89
2024 Q4	$3.22M	Buy	7,988 +63	+0.8%	+$29.2K	0.12%	96
2024 Q3	$3.69M	Sell	7,925 -161	-2%	-$77.3K	0.14%	87
2024 Q2	$3.79M	Sell	8,086 -152	-2%	-$66K	0.15%	81
2024 Q1	$3.44M	Sell	8,238 -301	-4%	-$127K	0.14%	89
2023 Q4	$3.47M	Buy	+8,539	New	+$3.15M	0.14%	89

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GLOBALT Investments's VRTX Position: Q2 2026 in Review

GLOBALT Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, selling an estimated $84.2K and leaving 4,583 shares worth $2.28M. The position accounts for 0.08% of the portfolio, ranked #112.

GLOBALT Investments first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.79M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

GLOBALT Investments held 4,583 shares of Vertex Pharmaceuticals worth $2.28M as of Q2 2026.
GLOBALT Investments sold 190 Vertex Pharmaceuticals shares in Q2 2026, an estimated $84.2K.
Vertex Pharmaceuticals made up 0.08% of GLOBALT Investments's portfolio in Q2 2026, its #112 holding.
GLOBALT Investments first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
GLOBALT Investments's Vertex Pharmaceuticals position peaked at $3.79M in Q2 2024.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on GLOBALT Investments's 13F filing for Q2 2026, filed 11 Aug 2026.